Duplication interne en tandem de FLT3 (ITD)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-FLT3-ITD |
|---|---|
| Type | Biomarqueur |
| Alias | FLT3 ITDFLT3-ITDFLT3-ITD-positive AMLВнутрішня тандемна дуплікація FLT3 (ITD) |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | DIS-AML DIS-B-ALL |
| Sources | SRC-ELN-AML-2022 SRC-NCCN-AML-2025 SRC-QUANTUM-FIRST-ERBA-2023 SRC-RATIFY-STONE-2017 |
Données biomarqueurs
| Type de biomarqueur | gene_mutation |
|---|---|
| Détails de la mutation | {"exon": "14-15 (domaine juxtamembrane)", "functional_impact":"activation constitutive FLT3 kinase par dimérisation", "gene": «FLT3», "gene_hugo_id": „HGNC:3765", "variant_type":« duplication interne en tandem»} |
| Mesure | MéthodePCR / fragment-length analysis (rapid TAT essential; required at AML diagnosis) OR NGS panel UnitésAllelic ratio (ITD-mutant : WT, e.g. 0.5 high-AR threshold per ELN-2017; ELN-2022 dropped AR threshold but still reported) Exigence de sensibilitéRapid PCR turn-around (≤72 h) required to inform 1L induction (midostaurin / quizartinib add-on per CALGB-10603 RATIFY / QuANTUM-First) |
| Biomarqueurs connexes | BIO-FLT3-D835 BIO-NPM1 |
Notes
~25% of newly diagnosed AML; high allelic ratio (≥0.5) historically associated with poorer outcomes (risk-stratifying in ELN-2017; ELN-2022 reclassified all FLT3-ITD as intermediate when NPM1-mutant irrespective of AR). Midostaurin + 7+3 (RATIFY) and quizartinib + 7+3 (QuANTUM-First) FDA-approved 1L. Gilteritinib (ADMIRAL) approved for relapsed/refractory FLT3-mutated AML. FLT3-ITD is also a maintenance target post-allo-HSCT (sorafenib SORMAIN; gilteritinib BMT-CTN-1506).
Utilisé par
Pertinence thérapeutique
BMA-FLT3-ITD-AML- FLT3-ITD in newly-diagnosed AML: midostaurin + 7+3 induction + high-dose cytarabine conso...BMA-FLT3-ITD-AML-RR- FLT3-ITD in relapsed/refractory AML: gilteritinib monotherapy superior to salvage chemo (...BMA-FLT3-ITD-B-ALL- FLT3-ITD in B-ALL is rare (~1-3% adult; enriched in MLL/KMT2A- rearranged infant ALL). Gi...
Biomarqueur
BIO-FLT3-D835- mutation du domaine tyrosine kinase (TKD) FLT3BIO-FLT3-F691L- FLT3 F691L gilteritinib- mutation de gardien de barrière de résistanceBIO-NPM1- mutation NPM1 (NPM1 cytoplasmique)